Equivocal Findings of Alzheimer’s Trial Using Young Blood
A small clinical trial testing the safety of administering young people’s blood plasma to treat Alzheimer’s disease has found that the approach may slightly improve
A small clinical trial testing the safety of administering young people’s blood plasma to treat Alzheimer’s disease has found that the approach may slightly improve
Neurodegenerative diseases are tough nuts to crack, not just because of the inherent difficulties of sorting through what has gone awry, and why, but also
In 2015, the global cost of Alzheimer’s disease was US$818 billion. That’s similar to the gross domestic product of the world’s 18th-largest economy. By 2030,
Microglia are phagocytic cells that remove cellular debris and aggregated proteins from the brain and prune unwanted and degenerating synapses (1). When the brain is
Microglia are phagocytic cells that remove cellular debris and aggregated proteins from the brain and prune unwanted and degenerating synapses (1). When the brain is
Deep brain stimulation can visit this website improve debilitating, treatment-resistant brain disorders but involves surgically implanting electrodes that often have to penetrate multiple layers of
Like many humans, non-human primates deposit copious misfolded Aβ protein in the brain as they age. Nevertheless, the complete behavioral and pathologic phenotype of Alzheimer’s
Peripheral clearance of amyloid-β (Aβ) by peritoneal dialysis could help to reduce the amyloid plaque burden in the brain, and might, therefore, represent a new
It’s no secret that fewer than 10 percent of investigational drugs achieve regulatory approval and reach the marketplace. But the chances of success for drugs
Neurodegenerative diseases are often associated with aging. To learn what happens within the aging brain and potentially gain information relevant to human health, researchers examined
Changes in gamma oscillations (20–50 Hz) have been observed in several neurological disorders. However, the relationship between gamma oscillations and cellular pathologies is unclear. Here we
Eli Lilly officials report that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a Phase III study of the drug in
In more than three dozen postmortem human brains, scientists have detected nanoparticles of magnetite that they suspect came from the environment. The brain produces magnetite
Amyloid-β proteins form plaques in the brain that are a hallmark of Alzheimer’s disease. Designed to clear these plaques, the antibody aducanumab is demonstrating early
Plaques of amyloid-β peptides in certain parts of the brain are a telltale sign of Alzheimer’s disease–associated neurodegeneration. When not in pathological aggregates, these peptides—found
The allele apolipoprotein E ε4 (APOE ε4) is the greatest genetic risk factor for Alzheimer’s disease (AD), but the role of the ApoE4 protein in
A new study from the Monell Center, the U.S. Department of Agriculture (USDA), and collaborating institutions reports a uniquely identifiable odor signature from mouse models
A new study from the Monell Center, the U.S. Department of Agriculture (USDA), and collaborating institutions reports a uniquely identifiable odor signature from mouse models
Removing built-up plaques of amyloid-β in the brain is a long-sought therapy for patients with Alzheimer’s disease, but for a variety of reasons, few treatments
Neurodegenerative diseases are often misdiagnosed due to overlapping symptoms, the lack of specific tests, and deficiencies in understanding the underlying pathogenesis of the disorders. However,
Created by ePubSystems. Contact Us for similar site for your university or institute.